Pharmacoepidemiology and drug safety
-
Pharmacoepidemiol Drug Saf · Mar 2008
Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture.
Evidence supports bone-specific drugs (BSDs) efficacy in the fracture risk reduction. But treatment rates for osteoporosis among high-risk patients are far below the recommended guidelines. A major concern about BSDs is the lack of adherence with treatment. ⋯ The incidence of fractures decreased by 16% among women with OP when more than 80% of BSDs was used for at least 3 years. Among women with a prior fracture, fracture risk reduction was not significant. Exposure to BSDs among women with a prior fracture is troubling, given that only approximately 12% of these individuals were being treated, and only 2% was using BSDs for the long term.
-
Pharmacoepidemiol Drug Saf · Mar 2008
Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population.
To estimate the frequency of exposure to prescription Food and Drug Administration (FDA) category C, D, and X drugs in pregnant women, and to analyze the maternal characteristics associated with such an exposure. ⋯ About 19.4% pregnant women are exposed to FDA C, D or X drugs during pregnancy. Women with chronic diseases, younger age, increased parity, and under social assistance are at increased risk of exposure to FDA C, D, or X drugs.